Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
Status:
Active, not recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The study is an open-label pilot study in newly diagnosed glioblastoma patients following
surgery. Eligible patients will receive treatment with tumor treating fields therapy using
the Optune device starting less than 2 weeks prior to start of chemoradiation. Patients will
receive radiation and temozolomide at a routine treatment dose and schedule.
Phase:
Phase 1
Details
Lead Sponsor:
Providence Health & Services
Collaborators:
NovoCure Ltd. Providence Health & Services Brain & Spine Institute University of California, San Francisco